Nasdaq First North-listed Qlucore, a leading provider of visualization-based software for research and companion diagnostics, will play an important role as one of five key partners in the OmegaPerMed project. The project aims to optimize treatment with omega-3 to prevent cardiovascular diseases (CVD).

Cardiovascular diseases, such as heart attack, stroke and angina, are the most common causes of death in populations, and therefore prevention is vital.

"This project is the starting point for the development of our solutions in a second major disease area – cardiovascular diseases. It complements our ongoing work in cancer areas such as leukemia and thus broadens the potential health benefit areas, says Carl-Johan Ivarsson, CEO of Qlucore.

In clinical trials, the project will try to detect interactions between genes, exposure to polyunsaturated fatty acid (PUFA), CVD risk and lipidomic markers against beneficial CVD effects of omega-3 PUFA. I This means that if successful, patients can be divided into subgroups in order to receive a more individualized treatment.

"We are providing the project with a machine learning software environment. We will develop artificial intelligence (AI) methods to build CVD-specific classification models that are easy to use for healthcare professionals with patient-friendly visualizations", says Carl-Johan Ivarsson. He continues:

"We are especially proud that our bioinformatician, Caroline Brorsson, is one of the project research leaders."

The project results for the optimization of omega-3 treatment may provide the first individually adapted treatment to be widely implemented under international guidelines for CVD treatment, potentially benefiting a large patient population in Europe and worldwide.

The project will be co ordinated by Professor Magnus Bäck at INSERM, France.